Back to results
US 10,376,600 B2Granted
Early disease detection and therapy
OwnerGholam A. Peymaninventor
Life of this patent
Estimating the term…
Abstract
A method for early stage pathology detection, location, imaging, evaluation, and treatment of cells and/or extracellular vesicles in the circulation.
Claims22
A method for early stage detection and treatment of a pathology in a patient, the method comprising the following steps:
- administering a pathology-specific antibody-coated nanoparticle into a patient's circulation, the pathology-specific antibody-coated nanoparticle comprising a nanoparticle bound to a pathology-specific antibody and further conjugated with an immune checkpoint inhibitor in the form of a monoclonal antibody, wherein the pathology-specific antibody and monoclonal antibody are different,
- allowing a time interval for the pathology-specific antibody of the antibody-coated nanoparticle to attach to a specific antigen in a circulating vesicle or cell,
- thereafter exciting the antibody-coated nanoparticle with an energy source in a retinal vessel in the patient to elicit a nanoparticle-specific wavelength of light response from the antibody-coated nanoparticle attached to the circulating vesicle or cell indicating an early stage pathology in the patient due to the presence of the specific antigen to which the pathology-specific antibody of the antibody-coated nanoparticle is bound,
- imaging and quantifying the nanoparticle-specific wavelength of light response in the retinal vessel in the patient for detection of the early stage pathology prior to a mass associated with the early stage pathology growing beyond a diameter of 3-4 mm and causing a clinical symptom, and
- treating the pathology using the monoclonal antibody so as to facilitate leukocyte mediated destruction, wherein the pathology is cancer.
2 more elements
A recognition and treatment method for an early stage of a tumor without producing a clinical symptom in a patient, the method comprising:
- defining a change in a tissue of a patient, the change indicating an early stage lesion in at least one cell in the tissue,
- administering a plurality of nanoparticles to the patient, where the nanoparticles are bound to an a lesion-specific antibody against a protein in the lesion and are coated with a thermosensitive polymer containing an immune checkpoint inhibitor in the form of a monoclonal antibody for therapy of the lesion, wherein the lesion-specific antibody and monoclonal antibody are different,
- interrogating the cellular and extracellular vesicles in the patient's blood using a photoacoustic spectroscopic system and an optical spectroscopic fundus camera equipped with a laser that is focused on a retinal vessel of the patient,
- recording, imaging, quantifying, and/or analyzing the patient's cells and extracellular vesicles according to the nanoparticles in the retinal vessel in the patient,
- treating the lesion using the immune checkpoint inhibitor so as to facilitate leukocyte mediated tumor destruction, and
- using the system to increase the temperature of the nanoparticles to a temperature of 42° C. to 43° C. to release the monoclonal antibody from the thermosensitive polymer to treat the lesion.
3 more elements
Dependencies are inferred from the claim text.